Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: vasopressin V2 receptor pharmacology
Also known as: DDAVP
Desmopressin acetate is an FDA-approved prescription analog of vasopressin. Oral intranasal sublingual and injectable products are not dose-equivalent. Water intoxication and potentially fatal hyponatremia are central safety concerns and require route-specific labeling fluid restriction and monitoring.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Current FDA-approved prescribing information
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
0.1-0.2 mg initially with individualized titration
Context: DailyMed desmopressin tablet labeling
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
10-40 ug/day with individualized division
Context: DailyMed nasal-spray labeling
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The prior 1 mg lyophilized-vial representation was not a standard U.S. product. Route-specific strengths and dose equivalence must remain separate.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.